To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
TQD3606 is a fixed-dose combination of meropenem and avibatam. This study is a phase I
clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of
TQD3606 injection in a single center, randomized, double-blind, placebo-controlled, single
and multiple administration in healthy subjects, and to explore the excretion of TQD3606 in
urine. To evaluate the tolerability and safety of injectable TQD3606 after single and
multiple dosing in healthy subjects.